Elevated GM3 plasma concentration in idiopathic Parkinson's disease: A lipidomic analysis

PLoS ONE

Volumn 12, Issue 2, 2017, Pages

  Chan, Robin B ^a   Perotte, Adler J ^a   Zhou, Bowen ^a   Liong, Christopher ^a   Shorr, Evan J ^a   Marder, Karen S ^a   Kang, Un J ^a   Waters, Cheryl H ^a   Levy, Oren A ^a   Xu, Yimeng ^a   Shim, Hong Bin ^a   Pe'Er, Itsik ^a   Di Paolo, Gilbert ^a,b   Alcalay, Roy N ^a  

^a NewYork Presbyterian Hospital   (United States)

^b Denali Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE GM3; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDE; GLYCEROLIPID; GLYCEROPHOSPHOLIPID; LEVODOPA; LIPID; SPHINGOLIPID; STEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME ACTIVITY; ENZYME SUBSTRATE; FEMALE; HUMAN; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPIDOMICS; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PARKINSON DISEASE; RECEIVER OPERATING CHARACTERISTIC; UNIFIED PARKINSON DISEASE RATING SCALE; UNITED STATES; UNIVERSITY HOSPITAL; BLOOD; CASE CONTROL STUDY; MIDDLE AGED; PATHOPHYSIOLOGY; SEXUAL DEVELOPMENT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; G(M3) GANGLIOSIDE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; SEX CHARACTERISTICS;

EID: 85013059646     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0172348     Document Type: Article

References (48)

1. Di Paolo G, Kim TW (2011) Linking lipids to Alzheimer's disease: cholesterol and beyond. Nature Reviews Neuroscience 12: 284-296. doi: 10.1038/nrn3012 PMID: 21448224
2. Block RC, Dorsey ER, Beck CA, Brenna JT, Shoulson I (2010) Altered cholesterol and fatty acid metabolism in Huntington disease. J Clin Lipidol 4: 17-23. doi: 10.1016/j.jacl.2009.11.003 PMID: 20802793
3. Ruiperez V, Darios F, Davletov B (2010) Alpha-synuclein, lipids and Parkinson's disease. Prog Lipid Res 49: 420-428. doi: 10.1016/j.plipres.2010.05.004 PMID: 20580911
4. Mattson MP (2004) Metal-catalyzed disruption of membrane protein and lipid signaling in the pathogenesis of neurodegenerative disorders. Ann N Y Acad Sci 1012: 37-50. PMID: 15105254
5. Iyer A, Petersen NO, Claessens MM, Subramaniam V (2014) Amyloids of alpha-synuclein affect the structure and dynamics of supported lipid bilayers. Biophys J 106: 2585-2594. doi: 10.1016/j.bpj.2014. 05.001 PMID: 24940776
6. Auluck PK, Caraveo G, Lindquist S (2010) alpha-Synuclein: membrane interactions and toxicity in Parkinson's disease. Annu Rev Cell Dev Biol 26: 211-233. doi: 10.1146/annurev.cellbio.042308.113313 PMID: 20500090
7. Kolter T, Sandhoff K (2010) Lysosomal degradation of membrane lipids. FEBS Lett 584: 1700-1712. doi: 10.1016/j.febslet.2009.10.021 PMID: 19836391
8. Jenco JM, Rawlingson A, Daniels B, Morris AJ (1998) Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. Biochemistry 37: 4901-4909. doi: 10.1021/bi972776r PMID: 9538008
9. Murphy KE, Halliday GM (2014) Glucocerebrosidase deficits in sporadic Parkinson disease. Autophagy 10: 1350-1351. doi: 10.4161/auto.29074 PMID: 24915553
10. Gan-Or Z, Ozelius LJ, Bar-Shira A, Saunders-Pullman R, Mirelman A, Kornreich R, et al. (2013) The p. L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease. Neurology 80: 1606-1610. doi: 10.1212/WNL.0b013e31828f180e PMID: 23535491
11. Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, et al. (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 46: 989-993. doi: 10.1038/ng.3043 PMID: 25064009
12. Manzoni C, Lewis PA (2013) Dysfunction of the autophagy/lysosomal degradation pathway is a shared feature of the genetic synucleinopathies. FASEB J 27: 3424-3429. doi: 10.1096/fj.12-223842 PMID: 23682122
13. Clague MJ, Rochin L (2016) Parkinson's Disease: A Traffic Jam? Curr Biol 26: R332-334. doi: 10. 1016/j.cub.2016.03.001 PMID: 27115692
14. Pan P-Y, Yue Z (2014) Genetic causes of Parkinson's disease and their links to autophagy regulation. Parkinsonism & Related Disorders 20: S154-S157.
15. Pilsl A, Winklhofer KF (2012) Parkin, PINK1 and mitochondrial integrity: emerging concepts of mitochondrial dysfunction in Parkinson's disease. Acta Neuropathol 123: 173-188. doi: 10.1007/s00401- 011-0902-3 PMID: 22057787
16. Small SA, Petsko GA (2015) Retromer in Alzheimer disease, Parkinson disease and other neurological disorders. Nat Rev Neurosci 16: 126-132. doi: 10.1038/nrn3896 PMID: 25669742
17. Qiang JK, Wong YC, Siderowf A, Hurtig HI, Xie SX, Lee VM, et al. (2013) Plasma apolipoprotein A1 as a biomarker for Parkinson disease. Ann Neurol 74: 119-127. doi: 10.1002/ana.23872 PMID: 23447138
18. Li Z, Zhang J, Sun H (2015) Increased plasma levels of phospholipid in Parkinson's disease with mild cognitive impairment. J Clin Neurosci 22: 1268-1271. doi: 10.1016/j.jocn.2015.02.013 PMID: 26055959
19. Mielke MM, Maetzler W, Haughey NJ, Bandaru VV, Savica R, Deuschle C, et al. (2013) Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study. PLoS One 8: e73094. doi: 10.1371/journal.pone.0073094 PMID: 24058461
20. Bjorkhem I, Lovgren-Sandblom A, Leoni V, Meaney S, Brodin L, Salveson L, et al. (2013) Oxysterols and Parkinson's disease: evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the disease. Neurosci Lett 555: 102-105. doi: 10.1016/j.neulet.2013.09.003 PMID: 24035896
21. Swanson CR, Berlyand Y, Xie SX, Alcalay RN, Chahine LM, Chen-Plotkin AS (2015) Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson's disease patients. Mov Disord 30: 1648-1656. doi: 10.1002/mds.26290 PMID: 26207725
22. Sakanaka K, Waters CH, Levy OA, Louis ED, Chung WK, Marder KS, et al. (2014) Knowledge of and interest in genetic results among Parkinson disease patients and caregivers. J Genet Couns 23: 114-120. doi: 10.1007/s10897-013-9618-y PMID: 23748874
23. Marder K, Levy G, Louis ED, Mejia-Santana H, Cote L, Andrews H, et al. (2003) Accuracy of family history data on Parkinson's disease. Neurology 61: 18-23. PMID: 12847150
24. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53: 695-699. doi: 10.1111/j.1532-5415.2005.53221.x PMID: 15817019
25. Chan RB, Oliveira TG, Cortes EP, Honig LS, Duff KE, Small SA, et al. (2012) Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem 287: 2678-2688. doi: 10. 1074/jbc.M111.274142 PMID: 22134919
26. Gulati S, Ekland EH, Ruggles KV, Chan RB, Jayabalasingham B, Zhou B, et al. (2015) Profiling the Essential Nature of Lipid Metabolism in Asexual Blood and Gametocyte Stages of Plasmodium falciparum. Cell Host Microbe 18: 371-381. doi: 10.1016/j.chom.2015.08.003 PMID: 26355219
27. Storey JD, Tibshirani R (2003) Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 100: 9440-9445. doi: 10.1073/pnas.1530509100 PMID: 12883005
28. Weir JM, Wong G, Barlow CK, Greeve MA, Kowalczyk A, Almasy L, et al. (2013) Plasma lipid profiling in a large population-based cohort. J Lipid Res 54: 2898-2908. doi: 10.1194/jlr.P035808 PMID: 23868910
29. Blanz J, Saftig P (2016) Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance. J Neurochem.
30. Alcalay RN, Dinur T, Quinn T, Sakanaka K, Levy O, Waters C, et al. (2014) Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol 71: 752-757. doi: 10.1001/jamaneurol.2014.313 PMID: 24756352
31. Proia RL (2004) Gangliosides help stabilize the brain. Nat Genet 36: 1147-1148. doi: 10.1038/ng1104- 1147 PMID: 15514666
32. Murphy KE, Gysbers AM, Abbott SK, Tayebi N, Kim WS, Sidransky E, et al. (2014) Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson's disease. Brain 137: 834-848. doi: 10.1093/brain/awt367 PMID: 24477431
33. Chiasserini D, Paciotti S, Eusebi P, Persichetti E, Tasegian A, Kurzawa-Akanbi M, et al. (2015) Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies. Mol Neurodegener 10: 15. doi: 10.1186/s13024-015-0010-2 PMID: 25881142
34. Gegg ME, Burke D, Heales SJ, Cooper JM, Hardy J, Wood NW, et al. (2012) Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol 72: 455-463. doi: 10.1002/ana. 23614 PMID: 23034917
35. Alcalay RN, Levy OA, Waters CC, Fahn S, Ford B, Kuo SH, et al. (2015) Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain 138: 2648-2658. doi: 10.1093/brain/ awv179 PMID: 26117366
36. Kim HJ, Jeon B, Song J, Lee WW, Park H, Shin CW (2016) Leukocyte glucocerebrosidase and betahexosaminidase activity in sporadic and genetic Parkinson disease. Parkinsonism Relat Disord 23: 99-101. doi: 10.1016/j.parkreldis.2015.12.002 PMID: 26705847
37. Papagiannakis N, Xilouri M, Koros C, Stamelou M, Antonelou R, Maniati M, et al. (2015) Lysosomal alterations in peripheral blood mononuclear cells of Parkinson's disease patients. Mov Disord 30: 1830-1834. doi: 10.1002/mds.26433 PMID: 26769460
38. Ghauharali-van der Vlugt K, Langeveld M, Poppema A, Kuiper S, Hollak CE, Aerts JM, et al. (2008) Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease. Clin Chim Acta 389: 109-113. doi: 10.1016/j.cca.2007.12.001 PMID: 18164265
39. Meikle PJ, Whitfield PD, Rozaklis T, Blacklock D, Duplock S, Elstein D, et al. (2008) Plasma lipids are altered in Gaucher disease: biochemical markers to evaluate therapeutic intervention. Blood Cells Mol Dis 40: 420-427. doi: 10.1016/j.bcmd.2007.10.004 PMID: 18054258
40. Svennerholm L, Bostrom K, Jungbjer B, Olsson L (1994) Membrane lipids of adult human brain: lipid composition of frontal and temporal lobe in subjects of age 20 to 100 years. J Neurochem 63: 1802-1811. PMID: 7931336
41. Clark LN, Chan R, Cheng R, Liu X, Park N, Parmalee N, et al. (2015) Gene-wise association of variants in four lysosomal storage disorder genes in neuropathologically confirmed Lewy body disease. PLoS One 10: e0125204. doi: 10.1371/journal.pone.0125204 PMID: 25933391
42. Gegg ME, Sweet L, Wang BH, Shihabuddin LS, Sardi SP, Schapira AHV (2015) No evidence for substrate accumulation in Parkinson brains with GBA mutations. Movement Disorders 30: 1085-1089. doi: 10.1002/mds.26278 PMID: 26096906
43. Di Pasquale E, Fantini J, Chahinian H, Maresca M, Taieb N, Yahi N (2010) Altered Ion Channel Formation by the Parkinson's-Disease-Linked E46K Mutant of alpha-Synuclein Is Corrected by GM3 but Not by GM1 Gangliosides. Journal of Molecular Biology 397: 202-218. doi: 10.1016/j.jmb.2010.01.046 PMID: 20114052
44. Grey M, Dunning CJ, Gaspar R, Grey C, Brundin P, Sparr E, et al. (2015) Acceleration of alpha-synuclein aggregation by exosomes. J Biol Chem 290: 2969-2982. doi: 10.1074/jbc.M114.585703 PMID: 25425650
45. Lee HJ, Bae EJ, Lee SJ (2014) Extracellular alpha-synuclein-a novel and crucial factor in Lewy body diseases. Nat Rev Neurol 10: 92-98. doi: 10.1038/nrneurol.2013.275 PMID: 24468877
46. Bray MS, Young ME (2011) Regulation of fatty acid metabolism by cell autonomous circadian clocks: time to fatten up on information? J Biol Chem 286: 11883-11889. doi: 10.1074/jbc.R110.214643 PMID: 21296875
47. Begum H, Li B, Shui G, Cazenave-Gassiot A, Soong R, Ong RT, et al. (2016) Discovering and validating between-subject variations in plasma lipids in healthy subjects. Sci Rep 6: 19139. doi: 10.1038/ srep19139 PMID: 26743939
48. Hodson L, McQuaid SE, Karpe F, Frayn KN, Fielding BA (2009) Differences in partitioning of meal fatty acids into blood lipid fractions: a comparison of linoleate, oleate, and palmitate. Am J Physiol Endocrinol Metab 296: E64-71. doi: 10.1152/ajpendo.90730.2008 PMID: 18940935